Evaluating New Markers for Minimal Residual Disease Analysis by Flow Cytometry in Precursor B Lymphoblastic Leukemia.

Autor: Jain S; 1Department of Pathology and Laboratory Services, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, New Delhi, 110085 India., Mehta A; 1Department of Pathology and Laboratory Services, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, New Delhi, 110085 India., Kapoor G; 3Department of Pediatric Hematology and Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, New Delhi, 110085 India., Bhurani D; 2Department of Hematooncology, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, New Delhi, 110085 India., Jain S; 3Department of Pediatric Hematology and Oncology, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, New Delhi, 110085 India., Agrawal N; 2Department of Hematooncology, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, New Delhi, 110085 India., Ahmed R; 2Department of Hematooncology, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, New Delhi, 110085 India., Kumar D; 1Department of Pathology and Laboratory Services, Rajiv Gandhi Cancer Institute and Research Centre, Sector - 5, Rohini, New Delhi, 110085 India.
Jazyk: angličtina
Zdroj: Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion [Indian J Hematol Blood Transfus] 2018 Jan; Vol. 34 (1), pp. 48-53. Date of Electronic Publication: 2017 Jul 03.
DOI: 10.1007/s12288-017-0845-5
Abstrakt: Minimal residual disease is currently the most powerful prognostic indicator in Precursor B lymphoblastic leukemia. Multiparameter flow cytometry is the most commonly used modality. Seventy three B ALL cases and 15 normal marrows were evaluated for expression patterns of leukemia markers (CD38, CD58, CD73) in all 73 cases and CD66c, CD86 and CD123 in 23 cases. CD73 was aberrantly expressed in 90.41% cases and CD86 in 60.87% B ALL cases. Thus addition of these markers in MRD panels can increase the sensitivity of the assay.
Competing Interests: Compliance with Ethical StandardsThe authors declare that they have no conflict of interest.Approval from Institute board for conducting the study was taken.No animals were included in the study.
Databáze: MEDLINE
Externí odkaz: